LASA.NSE · Lasa Supergenerics Limited

-

Please sign in to comment on LASA.NSE

1 Comment

Admin

4 years, 1 month ago

Lasa Supergenerics Limited is currently in a long term uptrend where the price is trading 2.6% above its 200 day moving average.

From a valuation standpoint, the stock is 77.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.

Lasa Supergenerics Limited's total revenue rose by 37.4% to $540M since the same quarter in the previous year.

Its net income has increased by 154.4% to $66M since the same quarter in the previous year.

Finally, its free cash flow grew by 111.3% to $242M since the same quarter in the previous year.

Based on the above factors, Lasa Supergenerics Limited gets an overall score of 5/5.

Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Exchange	NSE
CurrencyCode	INR
ISIN	INE670X01014

Market Cap	857M
PE Ratio	None
Beta	0.65
Target Price	None
Dividend Yield	None

ABOUT

Lasa Supergenerics Limited

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.

LASA.NSE · Lasa Supergenerics Limited

-

Lasa Supergenerics Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Lasa Supergenerics Limited using a moving average strategy